E. Schaefer

发表

A phase II single-arm study of LDK378 in patients with ALK-activated (ALK+) non-small cell lung cancer (NSCLC) previously treated with chemotherapy and crizotinib (CRZ).

H. Groen, G. Scagliotti, A. Weir, 2013 .

Safety and efficacy of buparlisib (BKM120) and chemotherapy in advanced, squamous non-small cell lung cancer (sqNSCLC): Results from the phase Ib/II BASALT-2 and BASALT-3 studies.

E. Felip, D. Planchard, L. Paz-Ares, 2016 .

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Young Hak Kim, N. Reinmuth, A. Chiang, 2019, The Lancet.

Feasibility of Large-Scale Implementation of an Electronic Patient-Reported Outcome Remote Monitoring System for Patients on Active Treatment at a Community Cancer Center

N. Cherny, C. Parrinello, T. Beck, 2022, JCO oncology practice.

Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non–Small Cell Lung Cancer: A Phase Ib Study

Edward S. Kim, K. Kelly, L. Paz-Ares, 2018, Clinical Cancer Research.

A Phase II Trial of Prexasertib (LY2606368) in Patients With Extensive-Stage Small-Cell Lung Cancer.

Melissa L. Johnson, L. Byers, A. Navarro, 2021, Clinical lung cancer.

Utilization and costs of epidermal growth factor receptor mutation testing and targeted therapy in Medicare patients with metastatic lung adenocarcinoma

P. Ma, C. Belani, Chan Shen, 2022, BMC Health Services Research.

Real-world performance of blood-based proteomic profiling in first-line immunotherapy treatment in advanced stage non-small cell lung cancer

R. B. Mitchell, W. Akerley, R. Page, 2021, Journal for ImmunoTherapy of Cancer.

Proactive management strategies for potential gastrointestinal adverse reactions with ceritinib in patients with advanced ALK-positive non-small-cell lung cancer

C. Baik, E. Schaefer, 2016, Cancer management and research.

Efficacy of Systemic Bevacizumab for Recurrent Respiratory Papillomatosis with Pulmonary Involvement.

D. Shin, T. Seiwert, S. Best, 2023, The Laryngoscope.

Phase 1b/2 trial of taladegib (LY2940680), a Hh/Smo inhibitor, in combination with carboplatin and etoposide followed by taladegib maintenance in extensive-stage small-cell lung cancer

D. Talbot, S. Estrem, F. Braiteh, 2016 .

The Role of Proteomic Testing in Improving Prognosis And Care Planning Quality Measures for Lung Cancer.

D. Nash, Alexandria Skoufalos, A. Argento, 2017, Managed care.

Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non–Small Cell Lung Cancer: A Phase Ib Study

Edward S. Kim, K. Kelly, L. Paz-Ares, 2018, Clinical Cancer Research.

First-in-human study of ABBV-011, a seizure-related homolog protein 6 (SEZ6)–targeting antibody-drug conjugate, in patients with small cell lung cancer.

A. Chiang, A. Tolcher, D. Carbone, 2023, Journal of Clinical Oncology.